Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi pasteur - purified diphtheria toxoid ph. eur.; purified tetanus toxoid; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus; haemophilus influenzae type b, conjugate with tetanus protein - powder for suspension for injection - 0.5 millilitre(s) - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi pasteur - diphtheria toxoid; tetanus toxoid; poliovirus, type 1; poliovirus, type 2; poliovirus, type 3 - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-poliomyelitis-tetanus

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi pasteur - purified tetanus toxoid; purified diphtheria toxoid ph. eur.; adsorbed purified pertussis toxoid; adsorbed purified filamentous haemagglutinin; inactivated poliomyelitis virus ph. eur; inactivated type 1 poliovirus; inactivated type 2 poliovirus; inactivated type 3 poliovirus - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-pertussis-poliomyelitis-tetanus

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Kanada - Inggeris - Health Canada

sanofi pasteur limited - poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated) - solution - 29unit; 7unit; 26unit - poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit - vaccines

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - human poliovirus type 3 inactivated; human poliovirus type 2 inactivated; human poliovirus type 1 inactivated; tetanus toxoid; diphtheria toxoid - suspension for injection

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection